Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091660 | 1.00 | ABCB1 (0.43) | ABCB1RIPK1RORCFFAR2HSD17B10 | |
| SCHEMBL13091670 | 1.00 | ABCB1 (0.43) | ABCB1RIPK1RORCFFAR2HSD17B10 | |
| SCHEMBL3075753 | 0.89 | ABCB1 (0.46) | ABCB1RIPK1RORCFFAR2HSD17B10 | |
| SCHEMBL3075751 | 0.89 | ABCB1 (0.46) | ABCB1RIPK1RORCFFAR2HSD17B10 | |
| SCHEMBL13091659 | 0.89 | ABCB1 (0.46) | ABCB1RIPK1RORCFFAR2HSD17B10 | |
| SCHEMBL13101308 | 0.89 | ABCB1 (0.46) | ABCB1RIPK1RORCFFAR2HSD17B10 | |
| SCHEMBL16775110 | 0.82 | ABCB1 (0.46) | ABCB1RIPK1RORCFFAR2HSD17B10 | |
| SCHEMBL14024616 | 0.81 | HSD17B10 (0.54) | ABCB1RIPK1FFAR2HSD17B10POLB | |
| SCHEMBL3072035 | 0.81 | HSD17B10 (0.54) | ABCB1RIPK1FFAR2HSD17B10POLB | |
| SCHEMBL6185805 | 0.81 | HSD17B10 (0.54) | ABCB1RIPK1FFAR2HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045401-B2 | Methods for treating or ameliorating a melanoma and killing melanoma cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-02 | — | — | US | disclosed |
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | LIPG, VEGFA, LIPE | ABCB1 1494/4885RIPK1 2547/4885RORC 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.